Citations

Clear

941 citation(s) found for "Tefferi, A".

Acute leukemia in pregnancy: a single institution experience with 23 patients
Farhadfar, Nosha , Cerquozzi, Sonia , Hessenauer, M.R., Litzow, Mark R. , Letendre, Louis, Patnaik, Mrinal M. , Tefferi, Ayalew , Gangat, Naseema , Hessenauer, Michael R, Hogan, William J.

Mayo Clinic

Leukemia & Lymphoma | August 26, 2016 | Volume: 58 | Issue: 5 | Pages: 1052-1060

10.1080/10428194.2016.1222379 | PMID 27562538 Get It

Somatic JAK2 mutations and their tumor phenotypes
Tefferi, Ayalew

Mayo Clinic

Blood | August 11, 2016 | Volume: 128 | Issue: 6 | Pages: 748-749

10.1182/blood-2016-06-722645 | PMID 27516428 Get It

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
Farhadfar, Nosha , Cerquozzi, Sonia , Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

Journal of Oncology Practice | July 12, 2016 | Volume: 12 | Issue: 7 | Pages: 611-621

10.1200/jop.2016.013268 | PMID 27407157 Get It

Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despite ongoing advancements, HSCT is associated with substantial morbidity and mortality, and the determination of which patients with myelofibrosis are ideal candidates and the selection of the opportune moment to proceed with transplantation remains challenging. This review summarizes our current recommendations for the role of and indications for HSCT in myelofibrosis.
The prognostic impact of bone marrow fibrosis in primary myelofibrosis
Elliott, Michelle A. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | June 25, 2016 | Volume: 91 | Issue: 10 | Pages: No page available

10.1002/ajh.24458 | PMID 27342701 Get It

Next‐generation sequencing in systemic mastocytosis: Derivation of a mutation‐augmented clinical prognostic model for survival
Pardanani, Animesh , Elala, Yoseph, Wassie, Emnet A, Finke, Christy M. , Reichard, Kaaren K. , Chen, Dong , Hanson, Curtis A. , Ketterling, Rhett P. , Tefferi, Ayalew , Wassie, Emnet, Lasho, Terra L. , Chen, Dong , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | May 24, 2016 | Volume: 91 | Issue: 9 | Pages: 888-893

10.1002/ajh.24426 | PMID 27214377 Get It

In routine practice, the World Health Organization classification of systemic mastocytosis (SM) is also the de facto prognostic system; a core value is distinguishing indolent (ISM) from advanced SM (includes aggressive SM [ASM], SM with associated hematological neoplasm [SM‐AHN] and mast cell leukemia [MCL]). We sequenced 27 genes in 150 SM patients to identify mutations that could be integrated into a clinical‐molecular prognostic model for survival. Forty four patients (29%) had ISM, 25 (17%) ASM, 80 (53%) SM‐AHN and 1 (0.7%) MCL; overall KITD816V prevalence was 75%. In 87 patients, 148 non‐KIT mutations were detected; the most frequently mutated genes were TET2 (29%), ASXL1 (17%), and CBL (11%), with significantly higher mutation frequency in SM‐AHN > ASM > ISM (P < 0.0001). In advanced SM, ASXL1 and RUNX1 mutations were associated with inferior survival. In multivariate analysis, age > 60 years (HR = 2.4), hemoglobin < 10 g/dL or transfusion‐dependence (HR = 1.7), platelet count < 150 × 109/L (HR = 3.2), serum albumin < 3.5 g/dL (HR = 2.6), and ASXL1 mutation (HR = 2.3) were associated with inferior survival. A mutation‐augmented prognostic scoring system (MAPSS) based on these parameters stratified advanced SM patients into high‐, intermediate‐, and low‐risk groups with median survival of 5, 21 and 86 months, respectively (P < 0.0001). These data should optimize risk‐stratification and treatment selection for advanced SM patients. Am. J. Hematol. 91:888–893, 2016. © 2016 Wiley Periodicals, Inc.
Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | May 17, 2016 | Volume: 91 | Issue: 6 | Pages: 631-642

10.1002/ajh.24396 | PMID 27185207 Get It

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder characterized by overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms. Diagnosis is based on the presence of persistent (>3 months) peripheral blood monocytosis (>1 × 109/L), along with bone marrow dysplasia. Clonal cytogenetic abnormalities occur in ∼20–30% of patients, while >90% have gene mutations. Mutations involving TET2 (∼60%), SRSF2 (∼50%), ASXL1 (∼40%), and RAS (∼30%) are frequent; with only ASXL1 mutations negatively impacting overall survival. Two molecularly integrated, CMML‐specific prognostic models include; the Groupe Français des Myélodysplasies (GFM) and the Molecular Mayo Model (MMM). The GFM model segregates patients into 3 groups based on: age >65 years, WBC >15 × 109/L, anemia, platelets <100 × 109/L, and ASXL1 mutation status, with respective median survivals of 56 (low), 27.4 (intermediate), and 9.2 (high) months. The MMM is based on ASXL1 mutational status, absolute monocyte count >10 × 109/L, hemoglobin <10 g/dL, platelets <100 × 109/L and circulating immature myeloid cells. This model stratifies patients into four groups; high (≥3 risk factors), intermediate‐2 (2 risk factors), intermediate‐1 (1 risk factor) and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively. Hypomethylating agents such as 5‐azacitidine and decitabine are commonly used, with overall response rates of ∼30–40% and complete remission rates of ∼7–17%. Allogeneic stem cell transplant is the only potentially curative option, but is associated with significant morbidity and mortality. Individualized therapy, including epigenetic modifiers and small molecule inhibitors, are exciting prospects. Am. J. Hematol. 91:632–642, 2016. © 2016 Wiley Periodicals, Inc.
A New Murine Monoclonal Antibody for the Diagnosis of Erythroleukemia
Oles, Karl J., Kimlinger, Teresa K. , Tefferi, Ayalew , Katzmann, Jerry A., Li, Chin Yang, Solberg, Lawrence A. , Li, Chin‐Yang

Mayo Clinic

American Journal of Clinical Pathology | March 17, 2016 | Volume: 93 | Issue: 3 | Pages: 387-390

10.1093/ajcp/93.3.387 | PMID 1689945 Get It

Correlation of Clinical Outcome with the Degree of Surface Immunoglobulin (sIg) Expression in B-Cell Chronic Lymphocytic Leukemia
Tefferi, Ayalew , Li, Chin‐Yang, Phyliky, Robert L.

Mayo Clinic

American Journal of Clinical Pathology | February 24, 2016 | Volume: 92 | Issue: 1 | Pages: 82-85

10.1093/ajcp/92.1.82 | PMID 2750712 Get It

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Elala, Yoseph, Gangat, Naseema , Finke, Christy M. , Barraco, Daniela , Haider, Mahnur , Hussein, Ahmed Kamel Abou, Hanson, Curtis A. , Ketterling, Rhett P. , Pardanani, Animesh , Tefferi, Ayalew , Elala, Yoseph C, Lasho, Terra L. , Abou Hussein, Ahmed K, Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | February 19, 2016 | Volume: 91 | Issue: 5 | Pages: 503-506

10.1002/ajh.24338 | PMID 26890983 Get It

About 85% of patients with essential thrombocythemia (ET) harbor one of three driver mutations: JAK2, calreticulin (CALR), and MPL; the remaining ( ∼15%) are wild type for all three mutations and are referred to as being “triple negative.” Furthermore, CALR mutations in ET are structurally classified as type 1/type 1‐like or type 2/type 2‐like variants. The objective of the current study was to examine the impact of CALR mutation variant stratified driver mutational status on overall (OS), myelofibrosis‐free (MFFS), thrombosis‐free, and leukemia‐free survival (LFS) in ET; 495 patients (median age 58 years; 61% females) with ET were fully annotated for the their driver mutational status: 321 (65%) harbored JAK2, 109 (22%) CALR, and 12 (2%) MPL mutations and 11% were triple‐negative. Among the 109 CALR‐mutated cases, 52% were classified as type 1/type 1‐like and 48% as type 2/type 2‐like. In univariate analysis, triple‐negative patients displayed the best and MPL mutated the worst OS (P = 0.007); however, the difference in OS was no longer apparent on multivariable analysis that included age and sex as covariates (P = 0.5). LFS was also similar among the different mutational groups (P = 0.6) whereas MFFS was significantly shorter in MPL‐mutated patients on both univariate and multivariable analyses (age‐adjusted P = 0.02; HR 7.9, 95% CI 2.0–31.5). Also in multivariable analysis that included thrombosis history, age, and cardiovascular risk factors, the presence of JAK2 or MPL mutations was independently associated with higher risk of thrombosis (P = 0.02; HR 1.9, 95% CI 1.1–3.4). In conclusion, driver mutational status in ET does not appear to influence overall or LFS, even after CALR variant stratification. However, the presence of MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2/MPL mutations with higher risk of thrombosis. Am. J. Hematol. 91:503–506, 2016. © 2016 Wiley Periodicals, Inc.
Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience
Haider, Mahnur , Gangat, Naseema , Hanson, Curtis A. , Tefferi, Ayalew , Hanson, Curtis

Mayo Clinic

American Journal of Hematology | February 14, 2016 | Volume: 91 | Issue: 5 | Pages: No page available

10.1002/ajh.24334 | PMID 26875150 Get It